Depemokimab, an ultra–long-acting anti–IL-5 biologic, showed significant efficacy in reducing nasal polyp scores and obstruction symptoms in patients with chronic rhinosinusitis with nasal polyps. The phase III ANCHOR-1 and ANCHOR-2 trials demonstrated a significant reduction in total endoscopic nasal polyps score, improved nasal obstruction, reduced Sino-Nasal Outcome Test 22 scores, and fewer patients requiring systemic corticosteroids or surgery among patients receiving the agent. Depemokimab also offers a reduced dosing schedule compared to existing biologics for CRSwNP, potentially reducing treatment burden, reported researchers.

Source: The Lancet